Immucell Corp /De/ financial data

Symbol
ICCC on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
56 Evergreen Dr, Portland, Maine
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 288 % -40.8%
Quick Ratio 188 % +4.18%
Debt-to-equity 71.1 % +52.8%
Return On Equity -15.2 % +12.1%
Return On Assets -8.89 % +24.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.75 M shares +0.05%
Common Stock, Shares, Outstanding 7.75 M shares +0.05%
Entity Public Float 31.2 M USD -51.6%
Common Stock, Value, Issued 781 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 7.75 M shares +0.05%
Weighted Average Number of Shares Outstanding, Diluted 7.75 M shares +0.05%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 5.4 M USD +12.5%
Research and Development Expense 4.55 M USD -0.47%
Selling and Marketing Expense 3.01 M USD -7.62%
General and Administrative Expense 2.1 M USD -2.17%
Operating Income (Loss) -3.79 M USD +26%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -3.89 M USD +26.7%
Income Tax Expense (Benefit) 4.44 K USD -44.8%
Net Income (Loss) Attributable to Parent -3.9 M USD +26.8%
Earnings Per Share, Basic -0.51 USD/shares +26.1%
Earnings Per Share, Diluted -0.51 USD/shares +26.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 960 K USD -69%
Cash, Cash Equivalents, and Short-term Investments 11.8 M USD +73.6%
Accounts Receivable, after Allowance for Credit Loss, Current 2.62 M USD +25.5%
Inventory, Net 7.15 M USD +13%
Other Assets, Current 57.7 K USD -24.8%
Assets, Current 11.3 M USD -7.35%
Property, Plant and Equipment, Net 27 M USD -5.2%
Operating Lease, Right-of-Use Asset 4.55 M USD +109%
Intangible Assets, Net (Excluding Goodwill) 43 K USD -30.8%
Goodwill 95.6 K USD 0%
Other Assets, Noncurrent 46.2 K USD -47.3%
Assets 43.1 M USD -0.17%
Liabilities, Current 4.18 M USD +9.02%
Long-term Debt and Lease Obligation 10.2 M USD
Operating Lease, Liability, Noncurrent 4.06 M USD +84%
Liabilities 18.4 M USD +23.1%
Retained Earnings (Accumulated Deficit) -12.4 M USD -45.6%
Stockholders' Equity Attributable to Parent 24.6 M USD -12.5%
Liabilities and Equity 43.1 M USD -0.17%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 419 K USD
Net Cash Provided by (Used in) Financing Activities -367 K USD -149%
Net Cash Provided by (Used in) Investing Activities -70.4 K USD +89.7%
Common Stock, Shares Authorized 15 M shares 0%
Common Stock, Shares, Issued 7.81 M shares 0%
Common Stock, Par or Stated Value Per Share 0.1 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 960 K USD -69%
Interest Paid, Excluding Capitalized Interest, Operating Activities 136 K USD +55%
Deferred Tax Assets, Valuation Allowance 4.03 M USD +48.9%
Deferred Tax Assets, Gross 665 K USD +752%
Operating Lease, Liability 4.66 M USD
Depreciation 2.71 M USD +8.17%
Payments to Acquire Property, Plant, and Equipment 70.4 K USD -89.7%
Lessee, Operating Lease, Liability, to be Paid 8.16 M USD
Property, Plant and Equipment, Gross 46.1 M USD +2.61%
Operating Lease, Liability, Current 597 K USD +1659%
Lessee, Operating Lease, Liability, to be Paid, Year Two 350 K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 343 K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure +36.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.51 M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 357 K USD
Deferred Tax Assets, Operating Loss Carryforwards 3.73 M USD +14.5%
Current Income Tax Expense (Benefit) 8.43 K USD -26.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 364 K USD
Operating Lease, Payments 144 K USD +369%
Additional Paid in Capital 36.2 M USD +0.9%
Amortization of Intangible Assets 19.1 K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 354 K USD +14.8%
Interest Expense 532 K USD +46.3%